Key result
Intra-operative dexmedetomidine improves renal function and hemodynamics versus placebo in malignant obstructive jaundice.
Why the study?
The study was designed to investigate the effects of intra-operative dexmedetomidine administration on hemodynamics and renal function in patients with malignant obstructive jaundice.
Does intra-operative dexmedetomidine improve hemodynamics and renal function in patients with malignant obstructive jaundice?
RCT (n=40)
Double-blind
Randomly divided
No
Does intra-operative dexmedetomidine improve hemodynamics and renal function in patients with malignant obstructive jaundice?
p-value: p=<0.05
Intra-operative dexmedetomidine improves hemodynamic stability and renal function, and shortens hospital stay in patients with malignant obstructive jaundice.
Supports dexmedetomidine for hemodynamic and renal protection in malignant obstructive jaundice surgery; extends RCT evidence to this high-risk population.
BACKGROUND This study aimed to investigate effects of intra-operative administration with dexmedetomidine (Dex) on hemodynamics and renal function in patients with malignant obstructive jaundice. MATERIAL AND METHODS Our randomized, double-blinded, placebo-controlled study was conducted among 40 patients with malignant obstructive jaundice between August 2009 and March 2011 in The Affiliated Hospital of Inner Mongolia Medical University. The 40 patients were randomly divided into 2 groups: the Dex group (receiving Dex 0.5 μg/kg 10-minutes before induction and then a 0.5 μg/kg/hour maintenance infusion until end of operation 30 minutes) and the Control group (receiving normal saline of same amount and at same rate). The adverse events, including incidence of cardiovascular complications and nausea and vomiting, and length of hospital stay were determined. The level of cystatin C (CysC), retinol-binding protein (RBP), creatinine (Scr), and blood urea nitrogen (BUN) were also evaluated. RESULTS Dexmedetomidine administration significantly decreased heart rate (HR) and stroke volume variation (SVV) and significantly increased capital venous pressure (CVP) and mean arterial pressure (MAP) values compared to that in the Control group (P<0.05). Dexmedetomidine administration significantly upregulated urine volume and significantly downregulated atropine levels compared to the Control group (P<0.05). Dexmedetomidine administration significantly improved renal functions, by modulating CysC, RBP, Scr and BUN levels compared to the Control group (P<0.05). Dexmedetomidine administration demonstrated no additional side-effects. Dexmedetomidine administration significantly shortened length of hospitalization in the Dex group compared to the Control group (P<0.05). CONCLUSIONS Dexmedetomidine plays preventive effects on renal dysfunction and hemodynamic stability in malignant obstructive jaundice patients during peri-operative period.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2019) conducted an RCT in Malignant obstructive jaundice (n=40). Dexmedetomidine vs. Placebo (normal saline) was evaluated on Hemodynamics and renal function (CysC, RBP, Scr, BUN) (p=<0.05). Intra-operative dexmedetomidine significantly improved renal function markers and hemodynamic stability compared to placebo in malignant obstructive jaundice patients (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: